Caribou Biosciences, Inc.
$2.29
▼
-2.51%
2026-04-21 06:12:01
cariboubio.com
NMS: CRBU
Explore Caribou Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$212.6 M
Current Price
$2.29
52W High / Low
$3.54 / $0.71
Stock P/E
—
Book Value
$1.28
Dividend Yield
—
ROCE
-90.82%
ROE
-78.97%
Face Value
—
EPS
$-1.59
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
97
Beta
2.46
Debt / Equity
22.29
Current Ratio
5.71
Quick Ratio
5.71
Forward P/E
-1.29
Price / Sales
16.71
Enterprise Value
$74.4 M
EV / EBITDA
-0.57
EV / Revenue
6.67
Rating
Strong Buy
Target Price
$11.12
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Jyong Biotech Ltd. | $2.31 | — | $185.51 M | — | 35.69% | 8.55% | $67 / $1.43 | $-0.31 |
| 2. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 3. | Bolt Biotherapeutics, Inc. | $5.15 | — | $9.09 M | — | -71.68% | -79.75% | $9.25 / $3.91 | $13.8 |
| 4. | Actuate Therapeutics, Inc. Common stock | $2.62 | — | $54.77 M | — | -270.08% | -5.54% | $11.99 / $1.58 | $0.34 |
| 5. | Phio Pharmaceuticals Corp. | $1.27 | — | $14.75 M | — | -45.76% | -69.95% | $4.19 / $0.81 | $1.73 |
| 6. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 7. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.94 M | 2.2 M | 2.67 M | 2.35 M | 2.08 M | — |
| Operating Profit | -28.45 M | -29.4 M | -35.43 M | -42.91 M | -38.88 M | — |
| Net Profit | -26.49 M | -27.55 M | -54.1 M | -39.99 M | -35.49 M | — |
| EPS in Rs | -0.27 | -0.29 | -0.56 | -0.41 | -0.37 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 11.16 M | 9.99 M | 34.48 M | 13.85 M |
| Operating Profit | -136.19 M | -166.62 M | -116.06 M | -106.4 M |
| Net Profit | -148.12 M | -149.1 M | -102.07 M | -99.42 M |
| EPS in Rs | -1.53 | -1.54 | -1.06 | -1.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 175.37 M | 313.31 M | 432.21 M | 373.76 M |
| Total Liabilities | 53.19 M | 60.36 M | 63.81 M | 72.89 M |
| Equity | 122.17 M | 252.95 M | 368.4 M | 300.87 M |
| Current Assets | 145.23 M | 219.38 M | 338.84 M | 260.25 M |
| Current Liabilities | 25.41 M | 30.65 M | 28.3 M | 28.13 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -110.99 M | -138.2 M | -93.29 M | -90.97 M |
| Investing CF | 102.24 M | 86.61 M | -68.18 M | -93.25 M |
| Financing CF | 4.82 M | 16.72 M | 154.3 M | 2.13 M |
| Free CF | -112.35 M | -144.71 M | -104.9 M | -98.02 M |
| Capex | -1.36 M | -6.5 M | -11.61 M | -7.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -71.01% | 148.91% | — | — |
| Earnings Growth % | -46.08% | -2.66% | — | — |
| Profit Margin % | -1491.95% | -296.05% | -717.79% | — |
| Operating Margin % | -1667.16% | -336.63% | -768.17% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1627.87% | -326.4% | -756.46% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.